IAVI, Moderna Kickstart HIV Vaccine Antigens Trial Delivered Through mRNA Technology

IAVI, the nonprofit scientific research organization, and Moderna Inc MRNA have administered the first doses of experimental HIV vaccine antigens in a clinical trial. 

• The Phase 1 trial, IAVI G002, is designed to test the hypothesis that sequential administration of priming and boosting HIV immunogens delivered by messenger RNA (mRNA) can induce specific B-cell responses and guide toward broadly neutralizing antibody (bnAbs) development. 
• The induction of bnAbs is widely considered a goal of HIV vaccination, which is the first step in that process. 
• The sites will enroll 56 healthy, HIV-negative adult volunteers. Forty-eight participants will receive one or two doses of eOD-GT8 60mer mRNA Vaccine (mRNA-1644), with 32 receiving the boost Core-g28v2 60mer mRNA Vaccine (mRNA-1644v2-Core). 
• An additional eight volunteers will receive the boost immunogen alone. Participants will be monitored for safety for six months after the last vaccination.
• Price Action: MRNA shares are down 2.65% at $150.86 during the market session on the last check Thursday.